Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea
Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
Most cases of travelers' diarrhea are caused by bacterial pathogens which respond slowly to
antibiotic treatment.The study was designed to determine the value of rapidly acting
loperamide (imodium) combined with curative dose of the poorly absorbed rifaximin in
travelers' diarreha treatment.
Phase:
Phase 4
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston
Collaborators:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.